NCT03515798 - Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

August 22, 2022

Study Completion Date

August 22, 2027

Conditions

Inflammatory Breast Cancer

Interventions

DRUG

Pembrolizumab Injection

Patients will receive intravenously 1 dose of Pembrolizumab every 3 weeks

DRUG

neoadjuvant EC-paclitaxel chemotherapy

The cytotoxic regimen is a combination of dose-dense EC, followed by weekly paclitaxel

Trial Locations (12)

Centre Georges Francois Leclerc, Dijon

Clinique de L'Europe, Amiens

Institut Sainte Catherine, Avignon

Institut BERGONIE, Bordeaux

CENTRE Francois Baclesse, Caen

Centre Leon Berard, Lyon

Institut Curie, Paris

Centre Henri Becquerel, Rouen

Institut Curie hopital rene huguenin, Saint-Cloud

Institut de cancérologie de la loire, Saint-Priest-en-Jarez

Centre Paul Strauss, Strasbourg

IUCT-Oncopole Institut Claudius Rigaud, Toulouse